This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 35.61% and 9.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
by Zacks Equity Research
Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
United Therapeutics Discontinues PAH Drug After Study Fails
by Zacks Equity Research
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
Company News For Apr 9, 2019
by Zacks Equity Research
Companies In The News Are: SNE, DLTR, UTHR, TWOU
United Therapeutics (UTHR) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.
Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal
by Zacks Equity Research
Regulatory news and licensing contracts are key highlights in the biotech sector this week.
Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
by Zacks Equity Research
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
United Therapeutics (UTHR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 14.04% and 10.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
by Zacks Equity Research
AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
by Zacks Equity Research
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
by Zacks Equity Research
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland
by Zacks Equity Research
Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland
UTHR vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. NBIX: Which Stock Is the Better Value Option?
5 Stocks Trading Near 52-Week High With More Upside in Store
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
BioLineRx Stock Up on Stake Increase in Lead Cancer Program
by Zacks Equity Research
BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.
Should Value Investors Pick United Therapeutics (UTHR) Stock?
by Zacks Equity Research
Is United Therapeutics (UTHR) a great pick from the value investor's perspective right now? Read on to know more.
United Therapeutics In-Licenses Rights to IPF Candidate
by Zacks Equity Research
United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals